GlassScriptPhysician profile
Fouad Malik
NPI 1790093540
$4,825.39
in general payments reported to CMS, 2019-2025
29 companies · $1,292 in 2025
The $1,292 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $860 · 2022: $859 · 2023: $964 · 2024: $850 · 2025: $1,292.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,106.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,658.89 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $379.20 | 2021-2025 | Caplyta |
| Gilead Sciences, INC. | $247.30 | 2022-2025 | |
| Uswm, LLC | $231.23 | 2022-2023 | Lucemyra, Zimhi |
| Otsuka America Pharmaceutical, INC. | $217.73 | 2021-2025 | Rexulti |
| Pfizer INC. | $199.89 | 2021-2025 | |
| Lilly USA, LLC | $191.38 | 2021-2024 | Zepbound, Jardiance, Emgality |
| Glaxosmithkline, LLC. | $176.29 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Alkermes, INC. | $167.51 | 2021-2025 | Aristada, Vivitrol, Lybalvi |
| Orexo US, INC. | $166.68 | 2022-2025 | Zubsolv |
| Novo Nordisk INC | $120.83 | 2024-2025 | Wegovy |
| Lundbeck LLC | $120.29 | 2022-2024 | Rexulti |
| Merck Sharp & Dohme LLC | $103.53 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ironwood Pharmaceuticals, INC | $103.22 | 2022-2023 | Linzess |
| Astrazeneca Pharmaceuticals LP | $102.08 | 2023-2025 | Airsupra, Breztri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $93.88 | 2024-2025 | Cologuard Collection Kit |
| Sunovion Pharmaceuticals INC. | $72.40 | 2021 | |
| Axsome Therapeutics, INC. | $70.96 | 2024-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $68.69 | 2021-2024 | Austedo Xr |
| Verona Pharma, INC. | $63.19 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $62.79 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $48.37 | 2022 | |
| Amgen INC. | $39.55 | 2021-2022 | |
| Braeburn INC. | $34.78 | 2023-2024 | Brixadi |
| Allergan, INC. | $21.28 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.80 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.02 | 2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $13.41 | 2022 | |
| Indivior INC. | $13.22 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fouad Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.